Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary

Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of... Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 CASE REPORT Oncogenic Activation of the Wnt/b-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary Janusz Kopczynski, MD,* Artur Kowalik, PhD,w Ma!gorzata Ch!opek, MS,w Zeng-Feng Wang, PhD,z Stanis!aw Go´z´dz´,MD,y8 Jerzy Lasota, MD,z and Markku Miettinen, MDz the ovary is characterized by the proliferation of stromal Abstract: Signet ring stromal cell tumor (SRSCT) of the ovary is spindle cells merged with rounded cells containing ec- a very rare benign ovarian neoplasm. To date, no underlying centric nuclei and single vacuoles, resulting in a signet genetic mechanism has been identified. In this study, 50 onco- ring cell-like appearance. The vacuoles contain no lipid, genes and tumor suppressor genes were evaluated for mutations mucoprotein, or glycogen. In general, nuclear atypia or in a typical SRSCT using the next-generation DNA sequencing mitotic activity is absent and no aggressive clinical out- approach. An in-frame deletion of 30 nucleotides in the glycogen come has ever been reported. Typically, SRSCT is vi- serine kinase-3 beta phosphorylation region of the b-catenin mentin positive, but epithelial membrane antigen gene (CTNNB1) was identified, and the finding was confirmed negative. The pathogenesis of SRSCT of the ovary is by Sanger http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary

Loading next page...
 
/lp/wolters-kluwer-health/oncogenic-activation-of-the-wnt-catenin-signaling-pathway-in-signet-7h8vsNKx6P

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1541-2016
eISSN
2475-5028
DOI
10.1097/PAI.0000000000000271
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 CASE REPORT Oncogenic Activation of the Wnt/b-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary Janusz Kopczynski, MD,* Artur Kowalik, PhD,w Ma!gorzata Ch!opek, MS,w Zeng-Feng Wang, PhD,z Stanis!aw Go´z´dz´,MD,y8 Jerzy Lasota, MD,z and Markku Miettinen, MDz the ovary is characterized by the proliferation of stromal Abstract: Signet ring stromal cell tumor (SRSCT) of the ovary is spindle cells merged with rounded cells containing ec- a very rare benign ovarian neoplasm. To date, no underlying centric nuclei and single vacuoles, resulting in a signet genetic mechanism has been identified. In this study, 50 onco- ring cell-like appearance. The vacuoles contain no lipid, genes and tumor suppressor genes were evaluated for mutations mucoprotein, or glycogen. In general, nuclear atypia or in a typical SRSCT using the next-generation DNA sequencing mitotic activity is absent and no aggressive clinical out- approach. An in-frame deletion of 30 nucleotides in the glycogen come has ever been reported. Typically, SRSCT is vi- serine kinase-3 beta phosphorylation region of the b-catenin mentin positive, but epithelial membrane antigen gene (CTNNB1) was identified, and the finding was confirmed negative. The pathogenesis of SRSCT of the ovary is by Sanger

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jun 1, 2016

There are no references for this article.